381229-74-9

Basic information

• Product Name: 4-methoxy-3,6-dichlorobenzaldehyde
• Synonyms: 4-methoxy-3,6-dichlorobenzaldehyde
• CAS NO: 381229-74-9
• Molecular Weight: 205.04
• Mol File: 381229-74-9.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-methoxy-3,6-dichlorobenzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 4-methoxy-3,6-dichlorobenzaldehyde(381229-74-9)
• EPA Substance Registry System: 4-methoxy-3,6-dichlorobenzaldehyde(381229-74-9)

Safety Data

• Hazardous Substances Data: 381229-74-9(Hazardous Substances Data)

Upstream product

• 4885-02-3 Dichloromethyl methyl ether 
• 1984-58-3 2,5-dichloroanisole 

Downstream Products

• 1445983-81-2 (R)-4-((2,5-dichloro-4-((4-(4-cyclopropyl-1,2,3,4-tetrahydroquinoxaline-1-carbonyl)thiazolidin-3-yl)methyl)phenoxy)methyl)benzoic acid 
• 1445984-09-7 (5-(2,5-dichloro-4-(((R)-4-(4-cyclopropyl-1,2,3,4-tetrahydroquinoxaline-1-carbonyl)thiazolidin-3-yl)methyl)phenyl)pentanoyl)-D-alanyl-D-alanyl-D-alanine 
• 1445984-60-0 (2S)-2-[5-(2,5-dichloro-4-[[(4R)-4-[(4-cyclopropyl-1,2,3,4-tetrahydroquinoxalin-1-yl)carbonyl]-1,3-thiazolidin-3-yl]methyl]phenyl)pentanamido]pentanedioic acid 
• 1445984-64-4 (R)-((3-(5-(2,5-dichloro-4-((4-(4-cyclopropyl-1,2,3,4-tetrahydroquinoxaline-1-carbonyl)thiazolidin-3-yl)methyl)phenyl)pentyl)ureido)methyl)phosphonic acid 
• 1445984-63-3 [(4-[[5-(2,5-dichloro-4-[[(4R)-4-[(4-cyclopropyl-1,2,3,4-tetrahydroquinoxalin-1-yl)carbonyl]-1,3-thiazolidin-3-yl]methyl]phenyl)pentyl]carbamoyl]piperazin-1-yl)methyl]phosphonic acid 
• 1445984-57-5 (R)-2,2'-((5-(2,5-dichloro-4-((4-(4-cyclopropyl-1,2,3,4-tetrahydroquinoxaline-1-carbonyl)thiazolidin-3-yl)methyl)phenyl)pentyl)azanediyl)diacetic acid 
• 1445984-20-2 5-(2,5-dichloro-4-(((R)-4-(4-cyclopropyl-1,2,3,4-tetrahydroquinoxaline-1-carbonyl)thiazolidin-3-yl)methyl)phenyl)-N-methyl-N-((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)pentanamide 
• 1445983-80-1 (R)-1-(5-(2,5-dichloro-4-((4-(4-cyclopropyl-1,2,3,4-tetrahydroquinoxaline-1-carbonyl)thiazolidin-3-yl)methyl)phenyl)pentyl)-3-(1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)urea 
• 1445983-93-6 (R)-1-(4-(2,5-dichloro-4-((4-(4-cyclopropyl-1,2,3,4-tetrahydroquinoxaline-1-carbonyl)thiazolidin-3-yl)methyl)phenyl)butyl)-3-(1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)urea 
• 1445985-81-8 (R)-(3-(4-(4-aminobutyl)-2,5-dichlorobenzyl)thiazolidin-4-yl)(4-cyclopropyl-3,4-dihydroquinoxalin-1(2H)-yl)methanone 
• 1445985-80-7 (R)-tert-butyl 4-(2,5-dicbloro-4-((4-(4-cyclopropyl-1,2,3,4-tetrahydroquinoxaline-1-carbonyl)thiazolidin-3-yl)methyl)phenyl)butylcarbamate 
• 1445985-79-4 tert-butyl N-[4-[2,5-dichloro-4-(hydroxymethyl)phenyl]butyl]carbamate 

Relevant articles and documents

Design of Gut-Restricted Thiazolidine Agonists of G Protein-Coupled Bile Acid Receptor 1 (GPBAR1, TGR5)

Bile acid signaling and metabolism in the gastrointestinal tract have wide-ranging influences on systemic disease. G protein-coupled bile acid receptor 1 (GPBAR1, TGR5) is one of the major effectors in bile acid sensing, with demonstrated influence on metabolic, inflammatory, and proliferative processes. The pharmacologic utility of TGR5 agonists has been limited by systemic target-related effects such as excessive gallbladder filling and blockade of gallbladder emptying. Gut-restricted TGR5 agonists, however, have the potential to avoid these side effects and consequently be developed into drugs with acceptable safety profiles. We describe the discovery and optimization of a series of gut-restricted TGR5 agonists that elicit a potent response in mice, with minimal gallbladder-related effects. The series includes 12 (TGR5 EC50: human, 143 nM; mouse, 1.2 nM), a compound with minimal systemic availability that may have therapeutic value to patients with type 2 diabetes mellitus, nonalcoholic steatohepatitis, or inflammatory bowel disease.

Discovery of novel p-arylthio cinnamides as antagonists of leukocyte function-associated antigen-1/intercellular adhesion molecule-1 interaction. 4. Structure - Activity relationship of substituents on the benzene ring of the cinnamide

We have shown that p-arylthio cinnamides can inhibit the interaction of LFA-1 and ICAM-1, which is involved in cell adhesion and the inflammatory process. We now show that 2,3-disubstitution on the aryl portion of the cinnamide results in enhanced activit